Edition:
United Kingdom

Dechra Pharmaceuticals PLC (DPH.L)

DPH.L on London Stock Exchange

2,348.00GBp
5:06pm BST
Change (% chg)

-14.00 (-0.59%)
Prev Close
2,362.00
Open
2,374.00
Day's High
2,376.00
Day's Low
2,340.00
Volume
427,678
Avg. Vol
294,361
52-wk High
3,180.48
52-wk Low
1,956.00

Latest Key Developments (Source: Significant Developments)

Dechra Says It Is Implementing Hard Brexit Mitigation Plan
Monday, 3 Sep 2018 

Sept 3 (Reuters) - Dechra Pharmaceuticals PLC ::FY REVENUE GROWTH OF 13.9% TO £407.1 MILLION.FULL YEAR DIVIDEND OF 25.50 PENCE.FY UNDERLYING OPERATING PROFIT GROWTH OF 24.0% TO £99.2 MILLION.NEW FINANCIAL YEAR HAS STARTED WELL AND IN LINE WITH MANAGEMENT EXPECTATIONS.PROPOSING A FINAL DIVIDEND OF 18.17 PENCE PER SHARE.ENGAGED IN CONTINGENCY PLANNING AND ARE IMPLEMENTING A HARD BREXIT MITIGATION PLAN.EXPECT FINANCIAL IMPACT OF HARD BREXIT MITIGATION PLAN TO BE IMMATERIAL.  Full Article

Dechra Says ‍Trading In Line With Management Expectations
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Dechra Pharmaceuticals Plc ::‍TRADING IN PERIOD WAS STRONG AND IN LINE WITH MANAGEMENT EXPECTATIONS​.‍REPORTED GROUP REVENUE FOR PERIOD INCREASED BY C.10.5% AT CONSTANT EXCHANGE RATE (CER) (C.11.5% AT ACTUAL EXCHANGE RATE (AER))​.  Full Article

Dechra Pharmaceuticals ‍Q1 performance in line with management expectations
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Dechra Pharmaceuticals Plc ::DECHRA PHARMACEUTICALS - ‍ PERFORMANCE IN Q1 OF FINANCIAL YEAR WAS IN LINE WITH MANAGEMENT EXPECTATIONS, WITH CONTINUED GROWTH ACROSS ALL OF ITS MARKETS​.  Full Article

Dechra Pharmaceuticals says full-year revenue up at 359.3 mln stg
Monday, 4 Sep 2017 

Sept 4 (Reuters) - Dechra Pharmaceuticals Plc ::Preliminary results announcement -year end 30.6.17.Fy revenue growth of 28.3% at constant exchange rates (cer).Fy underlying diluted eps growth of 35.1%; increase in full year dividend to 21.44 pence.Current trading is in line with board expectations and we anticipate delivering our strategic objectives in new financial year.In year, dechra delivered consolidated revenue of £359.3 million, representing an increase of 28.3% on prior year.Consolidated underlying operating profit of £81.3 million, represents a 36.9% increase on prior year.Underlying ebit margin increased by 140bps to 22.6%.  Full Article

UPDATE 1-Vectura reviewing drug stockpiles as no-deal Brexit looms

Sept 11 British drugmaker Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its mitigation plan for a "no-deal" Brexit and warned on Tuesday of a potential disruption to supply chains and higher costs.